[Failed to load article at https://consent.yahoo.com/v2/collectConsent?sessionId=1_cc-session_b6a21e74-e434-4191-b01a-a4ca090e87a1]


[Failed to load article at https://financialpost.com/pmn/business-wire-news-releases-pmn/citiustech-acquires-health-data-movers-enhances-healthcare-provider-offerings-with-epic-implementation-capabilities]


[Failed to load article at https://financialpost.com/pmn/business-wire-news-releases-pmn/sonitor-and-tagnos-announce-strategic-merger-paving-the-way-for-enhanced-healthcare-technology-solutions]


[TITLE]KKR Acquires Majority Stake in HealthCare Royalty Partners:
[TEXT]
KKR & Co. Inc. (NYSE:KKR) is one of the 11 Best Revenue Growth Stocks to Buy Now. On July 30, KKR & Co. Inc. (NYSE:KKR) announced that it has completed its acquisition of a majority ownership stake in HealthCare Royalty Partners (HCRx), which is a middle-market biopharma royalty acquisition company.

This deal will help KKR & Co. Inc. (NYSE:KKR) enhance its capabilities in biopharma royalty and credit investing. It will also add
[Source link]: https://finance.yahoo.com/news/kkr-acquires-majority-stake-healthcare-070311940.html

================================================================================

[Failed to load article at https://consent.yahoo.com/v2/collectConsent?sessionId=1_cc-session_b6a21e74-e434-4191-b01a-a4ca090e87a1]


[Failed to load article at https://financialpost.com/pmn/business-wire-news-releases-pmn/citiustech-acquires-health-data-movers-enhances-healthcare-provider-offerings-with-epic-implementation-capabilities]


[Failed to load article at https://financialpost.com/pmn/business-wire-news-releases-pmn/sonitor-and-tagnos-announce-strategic-merger-paving-the-way-for-enhanced-healthcare-technology-solutions]


[TITLE]KKR Acquires Majority Stake in HealthCare Royalty Partners:
[TEXT]
KKR & Co. Inc. (NYSE:KKR) is one of the 11 Best Revenue Growth Stocks to Buy Now. On July 30, KKR & Co. Inc. (NYSE:KKR) announced that it has completed its acquisition of a majority ownership stake in HealthCare Royalty Partners (HCRx), which is a middle-market biopharma royalty acquisition company.

This deal will help KKR & Co. Inc. (NYSE:KKR) enhance its capabilities in biopharma royalty and credit investing. It will also add
[Source link]: https://finance.yahoo.com/news/kkr-acquires-majority-stake-healthcare-070311940.html

================================================================================

[TITLE]Connor Clark & Lunn Investment Management Ltd. Decreases Holdings in PMV Pharmaceuticals, Inc. $PMVP:
[TEXT]
Connor Clark & Lunn Investment Management Ltd. cut its holdings in shares of PMV Pharmaceuticals, Inc. (NASDAQ:PMVP – Free Report) by 27.8% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 267,636 shares of the company’s stock after selling 103,284 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.52% of PMV Pharmaceuticals worth $292,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in PMVP. JPMorgan Chase & Co. increased its position in shares of PMV Pharmaceuticals by 2,282.8% during the 4th quarter. JPMorgan Chase & Co. now owns 24,591 shares of the company’s stock valued at $37,000 after purchasing an additional 23,559 shares during the last quarter. Velan Capital Investment Management LP purchased a new stake in shares of PMV Pharmaceuticals during the 4th quarter valued at $53,000. Squarepoint Ops LLC increased its position in shares of PMV Pharmaceuticals by 68.7% during the 4th quarter. Squarepoint Ops LLC now owns 73,015 shares of the company’s stock valued at $110,000 after purchasing an additional 29,722 shares during the last quarter. Northern Trust Corp increased its position in shares of PMV Pharmaceuticals by 23.2% during the 4th quarter. Northern Trust Corp now owns 107,340 shares of the company’s stock valued at $162,000 after purchasing an additional 20,190 shares during the last quarter. Finally, Bridgeway Capital Management LLC increased its position in shares of PMV Pharmaceuticals by 44.5% during the 4th quarter. Bridgeway Capital Management LLC now owns 202,100 shares of the company’s stock valued at $305,000 after purchasing an additional 62,200 shares during the last quarter. 90.20% of the stock is owned by hedge funds and other institutional investors.

Get PMV Pharmaceuticals alerts:

PMV Pharmaceuticals Price Performance

Shares of PMV Pharmaceuticals stock opened at $1.57 on Wednesday. PMV Pharmaceuticals, Inc. has a 1 year low of $0.81 and a 1 year high of $1.82. The firm has a market cap of $83.19 million, a PE ratio of -1.00 and a beta of 1.52. The stock has a fifty day moving average price of $1.30 and a 200-day moving average price of $1.18.

Insider Activity

PMV Pharmaceuticals ( NASDAQ:PMVP Get Free Report ) last announced its quarterly earnings data on Thursday, August 7th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.02). As a group, equities analysts anticipate that PMV Pharmaceuticals, Inc. will post -1.06 EPS for the current fiscal year.

In other PMV Pharmaceuticals news, CEO David Henry Mack sold 58,411 shares of the company’s stock in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $1.06, for a total transaction of $61,915.66. Following the sale, the chief executive officer directly owned 536,133 shares of the company’s stock, valued at $568,300.98. This represents a 9.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Deepika Jalota sold 33,065 shares of the company’s stock in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $1.06, for a total transaction of $35,048.90. Following the sale, the insider directly owned 89,959 shares in the company, valued at approximately $95,356.54. This trade represents a 26.88% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 114,627 shares of company stock worth $121,505. Insiders own 7.60% of the company’s stock.

PMV Pharmaceuticals Company Profile

(Free Report)

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.

Recommended Stories

Want to see what other hedge funds are holding PMVP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PMV Pharmaceuticals, Inc. (NASDAQ:PMVP – Free Report).

Receive News & Ratings for PMV Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PMV Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/08/20/connor-clark-lunn-investment-management-ltd-decreases-holdings-in-pmv-pharmaceuticals-inc-pmvp/


[TITLE]US Bancorp DE Invests $36,000 in Enanta Pharmaceuticals, Inc. $ENTA:
[TEXT]
US Bancorp DE bought a new position in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Free Report) in the 1st quarter, Holdings Channel.com reports. The institutional investor bought 6,500 shares of the biotechnology company’s stock, valued at approximately $36,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in ENTA. Tower Research Capital LLC TRC boosted its stake in Enanta Pharmaceuticals by 46.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 7,202 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 2,274 shares during the period. Invesco Ltd. boosted its stake in Enanta Pharmaceuticals by 7.3% in the 4th quarter. Invesco Ltd. now owns 46,614 shares of the biotechnology company’s stock valued at $268,000 after purchasing an additional 3,186 shares during the period. Wells Fargo & Company MN boosted its stake in Enanta Pharmaceuticals by 69.6% in the 4th quarter. Wells Fargo & Company MN now owns 15,881 shares of the biotechnology company’s stock valued at $91,000 after purchasing an additional 6,518 shares during the period. GAMMA Investing LLC bought a new stake in Enanta Pharmaceuticals in the 1st quarter valued at $40,000. Finally, Jane Street Group LLC boosted its stake in Enanta Pharmaceuticals by 34.1% in the 4th quarter. Jane Street Group LLC now owns 31,072 shares of the biotechnology company’s stock valued at $179,000 after purchasing an additional 7,896 shares during the period. 94.99% of the stock is currently owned by institutional investors.

Get Enanta Pharmaceuticals alerts:

Enanta Pharmaceuticals Stock Performance

NASDAQ:ENTA opened at $8.39 on Wednesday. The stock has a fifty day moving average price of $7.43 and a 200-day moving average price of $6.54. The company has a market cap of $179.38 million, a price-to-earnings ratio of -1.94 and a beta of 0.88. Enanta Pharmaceuticals, Inc. has a fifty-two week low of $4.09 and a fifty-two week high of $13.43.

Wall Street Analyst Weigh In

Enanta Pharmaceuticals ( NASDAQ:ENTA Get Free Report ) last released its earnings results on Monday, August 11th. The biotechnology company reported ($0.85) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.25) by $0.40. The firm had revenue of $18.31 million during the quarter, compared to the consensus estimate of $16.21 million. Enanta Pharmaceuticals had a negative return on equity of 89.02% and a negative net margin of 141.98%. Research analysts predict that Enanta Pharmaceuticals, Inc. will post -4.65 EPS for the current fiscal year.

ENTA has been the subject of several recent research reports. JMP Securities boosted their price target on Enanta Pharmaceuticals from $24.00 to $25.00 and gave the company a “market outperform” rating in a research note on Tuesday, August 12th. HC Wainwright initiated coverage on Enanta Pharmaceuticals in a research note on Monday, July 28th. They issued a “buy” rating and a $20.00 price target for the company. Finally, Wall Street Zen upgraded Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday, June 22nd. Three equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $21.67.

Read Our Latest Stock Report on ENTA

Enanta Pharmaceuticals Profile

(Free Report)

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.

Read More

Want to see what other hedge funds are holding ENTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Free Report).

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/08/20/us-bancorp-de-invests-36000-in-enanta-pharmaceuticals-inc-enta/


[TITLE]Vanguard Group Inc. Acquires 13,133 Shares of Supernus Pharmaceuticals, Inc. $SUPN:
[TEXT]
Vanguard Group Inc. grew its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report) by 0.2% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 6,163,892 shares of the specialty pharmaceutical company’s stock after acquiring an additional 13,133 shares during the quarter. Vanguard Group Inc. owned 0.11% of Supernus Pharmaceuticals worth $201,867,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of SUPN. LPL Financial LLC raised its holdings in Supernus Pharmaceuticals by 18.9% during the 4th quarter. LPL Financial LLC now owns 12,741 shares of the specialty pharmaceutical company’s stock worth $461,000 after buying an additional 2,029 shares during the period. Wells Fargo & Company MN lifted its position in Supernus Pharmaceuticals by 14.4% in the 4th quarter. Wells Fargo & Company MN now owns 63,237 shares of the specialty pharmaceutical company’s stock valued at $2,287,000 after acquiring an additional 7,961 shares in the last quarter. Envestnet Asset Management Inc. boosted its stake in Supernus Pharmaceuticals by 6.2% in the 4th quarter. Envestnet Asset Management Inc. now owns 59,970 shares of the specialty pharmaceutical company’s stock worth $2,169,000 after purchasing an additional 3,495 shares during the period. Bank of Montreal Can grew its holdings in shares of Supernus Pharmaceuticals by 6.6% during the fourth quarter. Bank of Montreal Can now owns 7,595 shares of the specialty pharmaceutical company’s stock worth $275,000 after buying an additional 473 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new stake in Supernus Pharmaceuticals in the 4th quarter valued at approximately $6,847,000.

Get Supernus Pharmaceuticals alerts:

Supernus Pharmaceuticals Stock Performance

Supernus Pharmaceuticals stock opened at $42.00 on Wednesday. The stock has a 50-day simple moving average of $34.75 and a 200 day simple moving average of $33.59. The stock has a market capitalization of $2.35 billion, a P/E ratio of 36.52 and a beta of 0.74. Supernus Pharmaceuticals, Inc. has a 52 week low of $29.16 and a 52 week high of $43.73.

Insider Buying and Selling at Supernus Pharmaceuticals

Wall Street Analysts Forecast Growth

In related news, Director Bethany Sensenig sold 5,369 shares of the company’s stock in a transaction dated Thursday, August 14th. The shares were sold at an average price of $42.25, for a total value of $226,840.25. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website . Also, CEO Jack A. Khattar sold 140,000 shares of the stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $42.02, for a total transaction of $5,882,800.00. Following the completion of the transaction, the chief executive officer directly owned 1,030,183 shares in the company, valued at approximately $43,288,289.66. This represents a 11.96% decrease in their ownership of the stock. The disclosure for this sale can be found here . Insiders have sold a total of 152,826 shares of company stock worth $6,424,773 over the last ninety days. Insiders own 8.80% of the company’s stock.

Several equities analysts have recently weighed in on the stock. Wall Street Zen raised shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, August 2nd. Cantor Fitzgerald lifted their price target on shares of Supernus Pharmaceuticals from $42.00 to $46.00 and gave the company an “overweight” rating in a research note on Wednesday, August 6th. Two analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $41.00.

Check Out Our Latest Research Report on Supernus Pharmaceuticals

Supernus Pharmaceuticals Company Profile

(Free Report)

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.

Further Reading

Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Free Report).

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/08/20/vanguard-group-inc-acquires-13133-shares-of-supernus-pharmaceuticals-inc-supn/


[TITLE]Charles Schwab Investment Management Inc. Sells 37,811 Shares of Ionis Pharmaceuticals, Inc. $IONS:
[TEXT]
Charles Schwab Investment Management Inc. decreased its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 2.6% during the first quarter, HoldingsChannel reports. The institutional investor owned 1,443,629 shares of the company’s stock after selling 37,811 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Ionis Pharmaceuticals were worth $43,554,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of IONS. IQ EQ FUND MANAGEMENT IRELAND Ltd bought a new position in Ionis Pharmaceuticals in the first quarter worth approximately $243,000. Raiffeisen Bank International AG grew its stake in Ionis Pharmaceuticals by 2,280.5% in the first quarter. Raiffeisen Bank International AG now owns 41,754 shares of the company’s stock worth $1,299,000 after purchasing an additional 40,000 shares in the last quarter. Privium Fund Management B.V. grew its stake in Ionis Pharmaceuticals by 0.3% in the first quarter. Privium Fund Management B.V. now owns 267,594 shares of the company’s stock worth $8,073,000 after purchasing an additional 800 shares in the last quarter. TD Asset Management Inc grew its stake in Ionis Pharmaceuticals by 4.8% in the first quarter. TD Asset Management Inc now owns 1,100,466 shares of the company’s stock worth $33,201,000 after purchasing an additional 50,476 shares in the last quarter. Finally, Pinnacle Associates Ltd. grew its stake in Ionis Pharmaceuticals by 11.1% in the first quarter. Pinnacle Associates Ltd. now owns 608,517 shares of the company’s stock worth $18,359,000 after purchasing an additional 60,875 shares in the last quarter. Institutional investors own 93.86% of the company’s stock.

Get Ionis Pharmaceuticals alerts:

Insiders Place Their Bets

In other news, EVP Eugene Schneider sold 9,549 shares of the stock in a transaction on Monday, August 4th. The stock was sold at an average price of $42.80, for a total transaction of $408,697.20. Following the completion of the sale, the executive vice president owned 51,507 shares in the company, valued at approximately $2,204,499.60. This represents a 15.64% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director B Lynne Parshall sold 5,000 shares of the stock in a transaction on Wednesday, August 6th. The shares were sold at an average price of $41.93, for a total value of $209,650.00. Following the sale, the director owned 86,344 shares of the company’s stock, valued at approximately $3,620,403.92. This represents a 5.47% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 28,141 shares of company stock worth $1,204,806. 2.60% of the stock is currently owned by company insiders.

Ionis Pharmaceuticals Stock Up 2.2%

Shares of NASDAQ IONS opened at $43.78 on Monday. The company has a current ratio of 2.87, a quick ratio of 2.86 and a debt-to-equity ratio of 0.99. The stock has a market capitalization of $6.98 billion, a PE ratio of -23.79 and a beta of 0.25. The stock’s fifty day simple moving average is $40.70 and its two-hundred day simple moving average is $34.77. Ionis Pharmaceuticals, Inc. has a 12-month low of $23.95 and a 12-month high of $50.43.

Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) last announced its earnings results on Wednesday, July 30th. The company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.19 by $0.51. Ionis Pharmaceuticals had a negative return on equity of 45.29% and a negative net margin of 28.25%. The business had revenue of $452.00 million for the quarter, compared to analysts’ expectations of $270.90 million. During the same quarter last year, the firm earned ($0.45) EPS. The business’s revenue for the quarter was up 100.9% on a year-over-year basis. As a group, analysts expect that Ionis Pharmaceuticals, Inc. will post -3.5 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently issued reports on IONS shares. Raymond James Financial increased their price objective on Ionis Pharmaceuticals from $60.00 to $64.00 and gave the stock a “strong-buy” rating in a research note on Thursday, July 31st. Barclays raised Ionis Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $51.00 to $57.00 in a research note on Tuesday, July 1st. JPMorgan Chase & Co. increased their price objective on Ionis Pharmaceuticals from $45.00 to $48.00 and gave the stock a “neutral” rating in a research note on Thursday, June 12th. HC Wainwright reissued a “buy” rating and issued a $65.00 price objective (up previously from $50.00) on shares of Ionis Pharmaceuticals in a research note on Thursday, July 31st. Finally, Morgan Stanley raised Ionis Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their price objective for the stock from $55.00 to $62.00 in a research note on Thursday, July 31st. Three equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $59.38.

Read Our Latest Research Report on Ionis Pharmaceuticals

Ionis Pharmaceuticals Company Profile

(Free Report)

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.

See Also

Want to see what other hedge funds are holding IONS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report).

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
[Source link]: https://www.etfdailynews.com/2025/08/18/charles-schwab-investment-management-inc-sells-37811-shares-of-ionis-pharmaceuticals-inc-ions/

================================================================================

[TITLE]Theratechnologies receives interim order in acquisition by CB Biotechnology THTX:
[TEXT]
Proprietary deal commentary available to members only.
[Source link]: https://thefly.com/permalinks/entry.php/id4184845/THTX-Theratechnologies-receives-interim-order-in-acquisition-by-CB-Biotechnology


[Failed to load article at https://financialpost.com/globe-newswire/theratechnologies-announces-filing-of-special-meeting-materials-and-receipt-of-interim-order-in-relation-to-its-acquisition-by-cb-biotechnology-an-affiliate-of-future-pak]


[TITLE]Theratechnologies Announces Filing of Special Meeting:
[TEXT]
Shareholders stand to receive a significant and attractive cash premium, as the purchase price of US$3.01, with a contingent value right for potential additional aggregate payments of up to US$1.19 per share, represents a compelling premium of 216% to the closing price on the Nasdaq on April 10, 2025, the date prior to the announcement of Future Pak’s initial non-binding proposal.

Board unanimously recommends shareholders vote “FOR” the Arrangement.

Shareholders are encouraged to review the circular carefully and submit their proxies in advance of the proxy voting deadline of 10:00 a.m. (Eastern time) on September 10, 2025.

Visit www.theratech.com
[Source link]: https://www.globenewswire.com/news-release/2025/08/18/3134927/0/en/Theratechnologies-Announces-Filing-of-Special-Meeting-Materials-and-Receipt-of-Interim-Order-in-Relation-to-its-Acquisition-by-CB-Biotechnology-an-Affiliate-of-Future-Pak.html

================================================================================

[Failed to load article at https://consent.yahoo.com/v2/collectConsent?sessionId=1_cc-session_b6a21e74-e434-4191-b01a-a4ca090e87a1]


[Failed to load article at https://financialpost.com/pmn/business-wire-news-releases-pmn/citiustech-acquires-health-data-movers-enhances-healthcare-provider-offerings-with-epic-implementation-capabilities]


[Failed to load article at https://financialpost.com/pmn/business-wire-news-releases-pmn/sonitor-and-tagnos-announce-strategic-merger-paving-the-way-for-enhanced-healthcare-technology-solutions]


[TITLE]KKR Acquires Majority Stake in HealthCare Royalty Partners:
[TEXT]
KKR & Co. Inc. (NYSE:KKR) is one of the 11 Best Revenue Growth Stocks to Buy Now. On July 30, KKR & Co. Inc. (NYSE:KKR) announced that it has completed its acquisition of a majority ownership stake in HealthCare Royalty Partners (HCRx), which is a middle-market biopharma royalty acquisition company.

This deal will help KKR & Co. Inc. (NYSE:KKR) enhance its capabilities in biopharma royalty and credit investing. It will also add
[Source link]: https://finance.yahoo.com/news/kkr-acquires-majority-stake-healthcare-070311940.html

================================================================================

